JP7849383B2 - コンジュゲートされたヘプシジン模倣物 - Google Patents

コンジュゲートされたヘプシジン模倣物

Info

Publication number
JP7849383B2
JP7849383B2 JP2023560496A JP2023560496A JP7849383B2 JP 7849383 B2 JP7849383 B2 JP 7849383B2 JP 2023560496 A JP2023560496 A JP 2023560496A JP 2023560496 A JP2023560496 A JP 2023560496A JP 7849383 B2 JP7849383 B2 JP 7849383B2
Authority
JP
Japan
Prior art keywords
lys
1peg2
hepcidin
ala
ahx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023560496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513391A5 (https=
JP2024513391A (ja
JPWO2022212700A5 (https=
Inventor
グレゴリー トーマス ボーン，
アショク バンダーリー，
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2024513391A publication Critical patent/JP2024513391A/ja
Publication of JP2024513391A5 publication Critical patent/JP2024513391A5/ja
Publication of JPWO2022212700A5 publication Critical patent/JPWO2022212700A5/ja
Application granted granted Critical
Publication of JP7849383B2 publication Critical patent/JP7849383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2023560496A 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物 Active JP7849383B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169545P 2021-04-01 2021-04-01
US63/169,545 2021-04-01
US202263325328P 2022-03-30 2022-03-30
US63/325,328 2022-03-30
PCT/US2022/022817 WO2022212700A2 (en) 2021-04-01 2022-03-31 Conjugated hepcidin mimetics

Publications (4)

Publication Number Publication Date
JP2024513391A JP2024513391A (ja) 2024-03-25
JP2024513391A5 JP2024513391A5 (https=) 2025-03-06
JPWO2022212700A5 JPWO2022212700A5 (https=) 2025-03-06
JP7849383B2 true JP7849383B2 (ja) 2026-04-21

Family

ID=83459967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560496A Active JP7849383B2 (ja) 2021-04-01 2022-03-31 コンジュゲートされたヘプシジン模倣物

Country Status (7)

Country Link
US (1) US20240209053A1 (https=)
EP (1) EP4314014A4 (https=)
JP (1) JP7849383B2 (https=)
AU (1) AU2022249097A1 (https=)
CA (1) CA3214153A1 (https=)
TW (1) TW202304952A (https=)
WO (1) WO2022212700A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008848A1 (en) 1999-05-18 2006-01-12 Verdine Gregory L Stabilized compounds having secondary structure motifs
US20100036089A1 (en) 2006-02-17 2010-02-11 Monash University Methods for the Synthesis of Dicarba Bridges in Organic Compounds
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152868A1 (en) * 2001-03-30 2004-08-05 Larsen Bjarne Due Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
CN102245626A (zh) * 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
US9624268B2 (en) * 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3749345A4 (en) * 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008848A1 (en) 1999-05-18 2006-01-12 Verdine Gregory L Stabilized compounds having secondary structure motifs
US20100036089A1 (en) 2006-02-17 2010-02-11 Monash University Methods for the Synthesis of Dicarba Bridges in Organic Compounds
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives

Also Published As

Publication number Publication date
US20240209053A1 (en) 2024-06-27
EP4314014A4 (en) 2025-03-05
JP2024513391A (ja) 2024-03-25
AU2022249097A1 (en) 2023-10-12
CA3214153A1 (en) 2022-10-06
WO2022212700A2 (en) 2022-10-06
WO2022212700A3 (en) 2022-12-08
EP4314014A2 (en) 2024-02-07
TW202304952A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
JP7849383B2 (ja) コンジュゲートされたヘプシジン模倣物
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
US12234300B2 (en) Conjugated hepcidin mimetics
JP7831841B2 (ja) コンジュゲートされたヘプシジン模倣物
JP2026048851A (ja) コンジュゲートされたヘプシジン模倣物
JP2024513392A (ja) コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) Conjugated hepcidin mimetics
EP4472996A2 (en) Conjugated hepcidin mimetics
EP4472995A2 (en) Conjugated hepcidin mimetics
CN117730089A (zh) 结合型铁调素模拟物
CN117813313A (zh) 结合型铁调素模拟物
CN117136192A (zh) 缀合的铁调素模拟物
WO2025226506A1 (en) Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm
EA053112B1 (ru) Конъюгированные миметики гепсидина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260409